RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer . 2015;136(5):E359–386.
   PubMed Web of Science ®Google Scholar
• Fu X, Huang Y, Fan X, et al. Demographic trends and KRAS/BRAF(V600E) mutations in colorectal cancer patients of South China: a single-site report. Int J Cancer. 2019;144:2109–2117.
   PubMed Web of Science ®Google Scholar
• Maley CC, Aktipis A, Graham TA, et al. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017;17(10):605–619.
   PubMed Web of Science ®Google Scholar
• Li C, Yu X, Lu J, et al. Contributions of gene modules regulated by essential noncoding RNA in colon adenocarcinoma progression. Biomed Res Int. 2020;2020:8595473.
   PubMed Web of Science ®Google Scholar
• Liu W, Li S. LncRNA ILF3-AS1 promotes the progression of colon adenocarcinoma cells through the miR-619-5p/CAMK1D Axis. Onco Targets Ther. 2021;14:1861–1872.
   PubMed Web of Science ®Google Scholar
• Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002;42(3):317–325.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xie Y, Xiong Y, et al. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Lett. 2020;469:173–185.
   PubMed Web of Science ®Google Scholar
• Lu H, Fang EF, Sykora P, et al. Senescence induced by RECQL4 dysfunction contributes to Rothmund-Thomson syndrome features in mice. Cell Death Dis. 2014;5(5):e1226.
   PubMedGoogle Scholar
• Popuri V, Tadokoro T, Croteau DL, et al. Human RECQL5: guarding the crossroads of DNA replication and transcription and providing backup capability. Crit Rev Biochem Mol Biol. 2013;48(3):289–299.
   PubMed Web of Science ®Google Scholar
• Su Y, Meador JA, Calaf GM, et al. Human RecQL4 helicase plays critical roles in prostate carcinogenesis. Cancer Res. 2010;70(22):9207–9217.
   PubMed Web of Science ®Google Scholar
• Fang H, Nie L, Chi Z, et al. RecQL4 helicase amplification is involved in human breast tumorigenesis. PLoS One. 2013;8(7):e69600.
   PubMed Web of Science ®Google Scholar
• Li J, Jin J, Liao M, et al. Upregulation of RECQL4 expression predicts poor prognosis in hepatocellular carcinoma. Oncol Lett. 2018;15:4248–4254.
   PubMedGoogle Scholar
• Mo D, Fang H, Niu K, et al. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cancer Res. 2016;76(10):3057–3066.
   PubMed Web of Science ®Google Scholar
• Lao VV, Welcsh P, Luo Y, et al. Altered RECQ helicase expression in sporadic primary colorectal cancers. Transl Oncol. 2013;6(4):458–469.
   PubMed Web of Science ®Google Scholar
• Han B, Ge Y, Cui J, et al. Down-regulation of lncRNA DNAJC3-AS1 inhibits colon cancer via regulating miR-214-3p/LIVIN axis. Bioengineered. 2020;11(1):524–535.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kang W, Lu X, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitroby regulating cell cycle pathway. Cell Cycle. 2018;17(15):1886–1900.
   PubMed Web of Science ®Google Scholar
• Xu G, Fan L, Zhao S, et al. Neuronal pentraxin II (NPTX2) hypermethylation promotes cell proliferation but inhibits cell cycle arrest and apoptosis in gastric cancer cells by suppressing the p53 signaling pathway. Bioengineered. 2021;12(1):1311–1323.
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, De Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193–204.
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.
   PubMed Web of Science ®Google Scholar
• Bahrami A, Khazaei M, Hasanzadeh M, et al. Therapeutic Potential of Targeting PI3K/AKT pathway in treatment of colorectal cancer: rational and progress. J Cell Biochem. 2018;119(3):2460–2469.
   PubMed Web of Science ®Google Scholar
• Xing Y, Ren S, Ai L, et al. ZNF692 promotes colon adenocarcinoma cell growth and metastasis by activating the PI3K/AKT pathway. Int J Oncol. 2019;54:1691–1703.
   PubMed Web of Science ®Google Scholar
• Lyu G, Su P, Hao X, et al. RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer. Cancer Biol Med. 2021;18:120–138.
   PubMed Web of Science ®Google Scholar
• Arora A, Agarwal D, Abdel-Fatah TM, et al. RECQL4 helicase has oncogenic potential in sporadic breast cancers. J Pathol. 2016;238(4):495–501.
   PubMed Web of Science ®Google Scholar
• Krol SK, Kaczmarczyk A, Wojnicki K, et al. Aberrantly expressed RECQL4 helicase supports proliferation and drug resistance of human glioma cells and glioma stem cells. Cancers (Basel). 2020;12(10):2919.
   Web of Science ®Google Scholar
• Jiang N, Dai Q, Su X, et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47:4587–4629.
   PubMed Web of Science ®Google Scholar
• Chen K, Abuduwufuer A, Zhang H, et al. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2019;23:6935–6943.
   PubMed Web of Science ®Google Scholar
• Fu X, Liu M, Qu S, et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018;37(1):52.
   PubMedGoogle Scholar
• Li Y, Zhai Z, Li H, et al. Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells. Chem Biol Interact. 2019;305:98–104.
   PubMed Web of Science ®Google Scholar